Literature DB >> 19463359

Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007.

Valerian L Fernandes1, Christopher Nielsen, Sherif F Nagueh, Amy E Herrin, Christine Slifka, Jennifer Franklin, William H Spencer.   

Abstract

OBJECTIVES: This study sought to determine the long-term outcome of alcohol septal ablation (ASA).
BACKGROUND: There are inadequate data on the long-term outcome of ASA for symptomatic hypertrophic obstructive cardiomyopathy (HOCM).
METHODS: Six hundred and twenty-nine patients were enrolled consecutively (1996 to 2007) and 98.4% (n = 619) underwent ASA with 92% follow-up in 2007. Evaluation included deaths, procedural complications, pacemaker requirement, repeat ASA, and myectomy/valve surgery. Follow-up parameters included angina (Canadian Cardiovascular Society score), dyspnea (New York Heart Association functional class), exercise time, and echocardiographic indices (septal thickness, ejection fraction, resting and provoked gradients).
RESULTS: Ethanol (2.6 +/- 1.0 ml) was injected into 1.3 +/- 0.5 septal arteries, inducing a septal infarct. Complications included death 1% (n = 6), permanent pacemaker requirement 8.2% (n = 52), coronary dissection 1.3% (n = 8), and worsening mitral regurgitation 0.3% (n = 2). The mean follow-up was 4.6 +/- 2.5 years (range: 3 months to 10.2 years). During follow-up, New York Heart Association functional class decreased from 2.8 +/- 0.6 to 1.2 +/- 0.5 (p < 0.001); Canadian Cardiovascular Society angina score decreased from 2.1 +/- 0.9 to 1.0 +/- 0 (p < 0.001); and exercise time increased from 4.8 +/- 3.3 to 8.2 +/- 1.0 (p < 0.001) min. The resting and provoked left ventricular outflow tract gradients decreased progressively (p < 0.001) and remained low during follow-up. The septal thickness decreased from 2.1 +/- 0.5 cm to 1.0 +/- 0.1 cm (p < 0.001) and the ejection fraction decreased from 68 +/- 9% to 62 +/- 3% (p < 0.001). The survival estimates at 1, 5, and 8 years were 97%, 92%, and 89%, respectively.
CONCLUSIONS: The initial benefits of ASA were maintained during follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19463359     DOI: 10.1016/j.jcin.2008.07.005

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  17 in total

Review 1.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 2.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

3.  Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model.

Authors:  Joseph D Foley; J Darrell Sneed; Steven R Steinhubl; Justin R Kolasa; Jeffrey L Ebersole; Yushun Lin; Richard J Kryscio; John T McDevitt; Charles L Campbell; Craig S Miller
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-09-28

Review 4.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

5.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis.

Authors:  Mohammed Osman; Babikir Kheiri; Khansa Osman; Mahmoud Barbarawi; Hani Alhamoud; Fahad Alqahtani; Mohamad Alkhouli
Journal:  Clin Cardiol       Date:  2018-11-29       Impact factor: 2.882

6.  Hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  Konstantinos I Stroumpoulis; Ioannis N Pantazopoulos; Theodoros T Xanthos
Journal:  World J Cardiol       Date:  2010-09-26

Review 7.  Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy.

Authors:  Libin Wang; Jonathan G Seidman; Christine E Seidman
Journal:  Ann Intern Med       Date:  2010-04-20       Impact factor: 25.391

Review 8.  The diagnosis and treatment of hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Martin Farr; Detlef Hering; Dieter Horstkotte; Lothar Faber
Journal:  Dtsch Arztebl Int       Date:  2011-04-01       Impact factor: 5.594

9.  Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.

Authors:  Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-11       Impact factor: 1.468

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.